|
Market Closed -
NSE India S.E.
06:05:06 2026-11-12 EST
|
5-day change | 1st Jan Change | ||
| 3,324.00 INR | +0.13% |
|
+0.22% | +20.05% |
| Market Cap | 415B 4.42B 3.99B 3.69B 3.34B 6.3B 6.49B 44.26B 17.59B 222B 16.58B 16.23B 707B | P/E 2027 * |
32.2x | P/E 2028 * | 28.3x |
|---|---|---|---|---|---|
| Enterprise Value | 407B 4.33B 3.92B 3.62B 3.27B 6.18B 6.36B 43.39B 17.24B 218B 16.26B 15.91B 693B | EV / Sales 2027 * |
6.36x | EV / Sales 2028 * | 5.6x |
| Free-Float |
36.41% | Yield 2027 * |
1.05% | Yield 2028 * | 1.22% |
| Markets | Quality | ||
|---|---|---|---|
NSE India S.E.
| AJANTPHARM | Delayed | |
Bombay S.E.
| AJANTPHARM | Delayed |
Last Transcript: Ajanta Pharma Limited
| 1 day | +0.13% | ||
| 1 week | +0.22% | ||
| Current month | -5.27% | ||
| 1 month | -2.52% | ||
| 3 months | -5.22% | ||
| 6 months | +8.48% | ||
| Current year | +20.05% |
| 1 week | 3,252.1 |  | 3,410.4 |
| 1 month | 3,199.9 | | 3,619.9 |
| Current year | 2,654.5 | | 3,796 |
| 1 year | 2,445.8 | | 3,796 |
| 3 years | 1,840.1 | | 3,796 |
| 5 years | 1,061.77 | | 3,796 |
| 10 years | 550 | | 3,796 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | - | |
| Chief Executive Officer | 54 | 2009-12-20 | |
| Director of Finance/CFO | 61 | 1998-04-22 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 54 | 1995-12-31 | |
| Chairman | 79 | 1979-12-30 | |
| Director/Board Member | 71 | 2009-12-20 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 2/28/25 | Sell | 548 | 0.0004% | |||
| 12/31/24 | Sell | 100 | 0.0001% | |||
| 12/31/24 | Sell | 51 | 0.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.13% | +0.22% | +28.96% | +76.07% | 4.42B | |
| +0.76% | +6.27% | +42.49% | +136.69% | 1,280B | |
| +1.73% | +4.92% | +46.99% | +93.54% | 675B | |
| +0.58% | +3.04% | +27.34% | +114.22% | 521B | |
| +1.14% | +3.78% | +39.98% | +70.26% | 386B | |
| +1.29% | +1.32% | +62.80% | +45.30% | 363B | |
| +1.11% | +0.07% | +28.19% | +58.61% | 301B | |
| +0.24% | -0.80% | +3.05% | +35.93% | 286B | |
| +0.64% | +2.47% | +40.26% | +76.85% | 253B | |
| +0.47% | +1.86% | +38.42% | +127.96% | 211B | |
| Average | +0.83% | -0.45% | +35.85% | +83.55% | 428B | |
| Weighted average by Cap. | +0.96% | +0.20% | +38.86% | +97.16% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 64.02B 681M 616M 568M 515M 971M 1B 6.82B 2.71B 34.22B 2.56B 2.5B 109B | 71.93B 765M 692M 639M 578M 1.09B 1.12B 7.67B 3.05B 38.45B 2.87B 2.81B 122B |
| Net income | 12.9B 137M 124M 115M 104M 196M 202M 1.38B 547M 6.9B 515M 504M 21.96B | 14.74B 157M 142M 131M 118M 224M 230M 1.57B 624M 7.88B 589M 576M 25.09B |
| Net Debt | -8.12B -86.38M -78.11M -72.1M -65.26M -123M -127M -865M -344M -4.34B -324M -317M -13.82B | -12.48B -133M -120M -111M -100M -189M -195M -1.33B -529M -6.67B -498M -488M -21.24B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-11-12 | ₹3,324.00 | +0.13% | 110,462 |
| 26-11-11 | ₹3,319.60 | -0.73% | 200,708 |
| 26-11-09 | ₹3,344.00 | +0.17% | 144,655 |
| 26-11-08 | ₹3,338.20 | +0.92% | 7,997 |
| 26-11-06 | ₹3,307.70 | +0.78% | 142,052 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- AJANTPHARM Stock
Select your edition
All financial news and data tailored to specific country editions
